Moexipril Hydrochloride and Hydrochlorothiazide (AvKARE, Inc.)
Welcome to the PulseAid listing for the Moexipril Hydrochloride and Hydrochlorothiazide drug offered from AvKARE, Inc.. This Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | AvKARE, Inc. |
| NON-PROPRIETARY NAME: | Moexipril Hydrochloride and Hydrochlorothiazide |
| SUBSTANCE NAME: | MOEXIPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET, FILM COATED |
| MARKETING CATEGORY NAME: | ANDA |
| START MARKETING DATE: | 2017-04-03 |
| END MARKETING DATE: | 0000-00-00 |
Moexipril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG Details:
| Item Description | Moexipril Hydrochloride and Hydrochlorothiazide from AvKARE, Inc. |
| LABELER NAME: | AvKARE, Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 7.5; 12.5(mg/1; mg/1) |
| START MARKETING DATE: | 2017-04-03 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 42291-576_e7ea7d06-70bc-46fc-b7bc-5e3d49bfa181 |
| PRODUCT NDC: | 42291-576 |
| APPLICATION NUMBER: | ANDA076980 |
Other MOEXIPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE Pharmaceutical Manufacturers / Labelers:
